nyuuzyou/wikis huggingface dataset:
Ganetespib (STA-9090)

==General information==
Class/mechanism: Small molecule inhibitor of Hsp90 (heat shock protein 90). Hsp90 is a molecular chaperone that stabilizes various cellular proteins, such as growth factor receptors and molecules involved in signal transduction. Hsp90 is overexpressed in cancer cells and may help to stabilize less stable proteins produced by DNA mutations. By inhibiting Hsp90, ganetespib is hypothesized to accelerate degradation of growth factors and increase the sensitivity of cancer cells to environmental stress, leading to apoptosis of tumor cells.Synta Pharmaceuticals' Ganetespib siteProia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu Y, Rosenberg AF, Zhou D, Koya K, Barsoum J, Blackman RK. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One. 2011 Apr 14;6(4):e18552. link to original article EuroPMC
Route: IV 
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, or the package insert. 
==Patient drug information==
No information available.
==Also known as==
*Code name: STA-9090
==References==
Category:Drugs
Category:Intravenous medications
Category:Hsp90 inhibitors
Category:Investigational drugs
Ganitumab (AMG-479)

==General information==
Class/mechanism: Human monoclonal antibody that targets IGF-1R (insulin-like growth factor 1 receptor). IGF-1R plays a role in cell survival and cell cycle progression via the PI3K/Akt pathway. Ganitumab's mechanism of action may involve: 1. inhibition of binding of IGF-1 and IGF-2 to IGF-1R; 2. blocking the action of IGF-1R homodimers and IGF-1R/INSR (insulin receptor) hybrid receptors; 3. downregulating expession of IGF-1R.Amgen drug development pipelineAMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
Route: IV 
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert. 
==Patient drug information==
No information available
==Also known as==
*Code name: AMG-479
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-IGF-1R antibodies
Category:Investigational drugs
Georgetown University Hospital Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The mission of the fellowship program of Georgetown University Medical Center's Division of Hematology/Oncology and Lombardi Cancer Center is to provide a balanced program of clinical training and research experience in order to develop the best clinicians and investigators in the country."
==Basic information==
Name: Georgetown University Medical Oncology-Hematology Fellowship Program 
Fellowship program website: https://lombardi.georgetown.edu/education/hematology
ACGME ID: 2024447036
===Leadership===
*Program Director: Ann Gramza, MD
===Fellowship Coordinator===
Adrian Hameed
Email: AH@gunet.georgetown.edu
==Application process and requirements==
https://medicine.georgetown.edu/divisions/hematology/hematology-education/the-application-process-division-of-hematology-and-oncology/
===Process===
*Applications accepted starting in: July
*Application deadline:
*Applications submitted through ERAS
*Interviews from August to October.
===Requirements===
*Common Application Form (CAF)
*Statement of Personal Goals
*At least three letters of recommendation; one must be from Residency Program Director or Internal Medicine Department Chair
*Foreign medical school graduates: ECFMG certification
*Color Photo
*USMLE transcripts
*Medical School transcripts
*Accept J1 Visa
==Statistics==
*Number of fellowship positions available per year: 4
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
https://medicine.georgetown.edu/divisions/hematology/hematology-education/hematology-fellowship/program/
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*Georgetown Lombardi Comprehensive Cancer Center
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Giant-cell tumor of bone

Back to Top
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Bone Cancer.
=All lines of therapy=
==Denosumab monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence
Thomas et. al 2010 (Amgen 20040215)	2006-2008 	Phase 2 (RT)
Chawla et al. 2013 (Amgen 20062004)	2008-2011 	Phase 2 (RT)
====Targeted therapy====
*Denosumab (Xgeva) as follows:
**Cycle 1: 120 mg SC once per day on days 1, 8, 15
**Cycle 2 onwards: 120 mg SC once on day 1
====Supportive therapy====
*Calcium 500 mg PO once per day
*Vitamin D 400 IU PO once per day
28-day cycles
===References===
# Amgen 20040215: Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. Epub 2010 Feb 10. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00396279
# Amgen 20062004: Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00680992
## Update: Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. link to original article EuroPMC
Category:Giant-cell tumor of bone regimens
Category:Disease-specific pages
Category:Bone sarcomas
Gilteritinib (Xospata)

==Mechanism of action==
Tyrosine kinase inhibitor of FLT3, AXL, and ALK
==Diseases for which it is used==
*FLT3+ AML
==History of changes in FDA indication==
*2018-11-28: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Based on ADMIRAL)
==History of changes in EMA indication==
*2019-10-24: Initial authorization
==History of changes in Health Canada indication==
*2019-12-23: Initial notice of compliance
==History of changes in PMDA indication==
*2018-09-21: New approval for the treatment of relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
== Patient Drug Information==
*Gilteritinib (Xospata) Package InsertGilteritinib (Xospata) Package Insert
==Also known as==
*Code name: ASP-2215
*Brand name: Xospata
==References==
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:Acute myeloid leukemia medications
Category:ALK inhibitors
Category:AXL inhibitors
Category:FLT3 inhibitors
Category:FDA approved in 2018
Category:EMA approved in 2019
Category:Health Canada approved in 2019
Category:PMDA approved in 2018
Giredestrant (GDC-9545)

==Mechanism of action==
From the NCI Drug Dictionary: An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Breast cancer, ER-positive===
#acelERA: Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno PD, Sohn J; acelERA Breast Cancer Study Investigators. Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. J Clin Oncol. 2024 Jun 20;42(18):2149-2160. Epub 2024 Mar 27. link to original article link to PMC article EuroPMC NCT04576455
==Also known as==
*Code names: GDC-9545, RG-6171
Category:Drugs
Category:Oral medications
Category:Estrogen receptor inhibitors
Category:Breast cancer medications (investigational)
Glasdegib (Daurismo)

==General information==
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling pathway with potential antineoplastic activity. Glasdegib appears to inhibit Hh pathway signaling.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is established==
*Acute myeloid leukemia
==History of changes in FDA indication==
*2018-11-21: Initial FDA approval for use in combination with low-dose cytarabine (LDAC), for newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years old or older or who have comorbidities that preclude intensive induction chemotherapy. (Based on BRIGHT AML 1003)
==History of changes in EMA indication==
*2020-06-26: Initial authorization
*Uncertain date: Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
== Patient Drug Information==
*Glasdegib (Daurismo) Package InsertGlasdegib (Daurismo) Package Insert
==Also known as==
*Code name: PF-04449913
*Brand name: Daurismo
==References==
Category:Drugs
Category:Oral medications
Category:Hedgehog pathway inhibitors
Category:Acute myeloid leukemia medications
Category:FDA approved in 2018
Category:EMA approved in 2020
Glioblastoma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main GBM page for regimens that include active anticancer treatment.
=First-line therapy=
==Best supportive care==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Keime-Guibert et al. 2007	2001-2005 	Phase 3 (C)	RT x 5000 cGy	Shorter OS
No antineoplastic therapy after primary surgery.
====Preceding treatment====
*Surgery
===References===
#BTSG 69-01: Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 1978 Sep;49(3):333-43. link to original article EuroPMC
#Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY; Association of French-Speaking Neuro-Oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 Apr 12;356(15):1527-35. link to original article EuroPMC NCT00430911
=Recurrent disease, non-curative therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Brem et al. 1995 	1989-1992 	Phase 3 (C)	Gliadel wafer	Shorter OS
Westphal et al. 2003	1997-1999 	Phase 3 (C)	Gliadel wafer	Seems to have shorter OS
No active antineoplastic treatment.
===References===
#Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC; Polymer-Brain Tumor Treatment Group. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995 Apr 22;345(8956):1008-12. link to original article EuroPMC
#Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003 Apr;5(2):79-88. link to original article link to PMC article EuroPMC
Category:Glioblastoma regimens
Category:Disease-specific pages
Category:High-grade gliomas
Category:Null regimens
Glofitamab (Columvi)

==Mechanism of action==
From the NCI Drug Dictionary: A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.
==Diseases for which it is used==
*Diffuse large B-cell lymphoma
*Transformed lymphoma
==History of changes in FDA indication==
*2023-06-15: Initial accelerated approval for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (Based on NP30179)
==Also known as==
*Code name: RO-7082859
*Generic name: glofitamab-gxbm
*Brand name: Columvi
Category:Drugs
Category:Intravenous medications
Category:Anti-CD20-CD3 bispecific antibodies
Category:Diffuse large B-cell lymphoma medications
Category:Transformed lymphoma medications
Category:FDA approved in 2023
Glucarpidase (Voraxaze)

==General information==
Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.Glucarpidase (Voraxaze) package insertGlucarpidase (Voraxaze) package insert (locally hosted backup)Glucarpidase (Voraxaze) manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Patient drug information==
*Brief patient counseling information can be found in the package insert.Glucarpidase (Voraxaze) package insert
*Glucarpidase (Voraxaze) patient drug information (UpToDate)Glucarpidase (Voraxaze) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2012-01-17: Initial FDA approval for the treatment of toxic plasma methotrexate concentrations (greater than 1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
==History of changes in PMDA indication==
*2021-09-27: Newly indicated to reduce toxic plasma methotrexate concentration in patients with delayed clearance of methotrexate due to methotrexate/leucovorin salvage therapy.
==Also known as==
*Generic name: carboxypeptidase G2
*Brand names: Megludase, Voraxaze
==References==
# Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G, Bode U, Fleischhack G. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005 Feb 14;92(3):480-7. link to original article link to PMC article EuroPMC
Category:Drugs
Category:Intravenous medications
Category:Chemotherapy protective agents
Category:FDA approved in 2012
Category:PMDA approved in 2021
Goserelin (Zoladex)

==General information==
Class/mechanism: Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesisGoserelin (Zoladex) package insert Goserelin (Zoladex) package insert (locally hosted backup)
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Breast cancer
*Prostate cancer
==Patient drug information==
*Patient counseling information can be found in the package insert
*Goserelin (Zoladex) patient drug information (Chemocare)Goserelin (Zoladex) patient drug information (Chemocare)
*Goserelin (Zoladex) patient drug information (UpToDate)Goserelin (Zoladex) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1989-12-29: Initial FDA approval for palliative treatment of advanced carcinoma of the prostate. (Based on Pilepich et al. 1995)
==History of changes in EMA indication==
The approval of this drug pre-dates the EMA.
*1987-05-12: EURD
==History of changes in PMDA indication==
*2014-03-17: New additional indication for the treatment of premenopausal breast cancer.
==Also known as==
*Generic name: goserelin acetate
*Brand names: Novgos, Zoladex
==References==
Category:Drugs
Category:Subcutaneous medications
Category:GnRH agonists
Category:Breast cancer medications
Category:Prostate cancer medications
Category:FDA approved in 1989
Category:EMA approved in 1987
Category:WHO Essential Cancer Medicine
Granisetron

==General information==
Class/mechanism: Selective serotonin 5-HT3 receptor antagonist. Chemotherapy medications can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Granisetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin. Granisetron does not block 5-HT1, 5-HT1A, 5-HT1B/C, 5-HT2, dopamine-D2, or histamine-H1 receptors.Granisetron (Kytril) package insert Granisetron (Kytril) package insert (locally hosted backup)Granisetron (Sancuso) package insert Granisetron (Sancuso) package insert (locally hosted backup)Sancuso manufacturer's websiteGranisetron (Sustol) package insert Granisetron (Sustol) package insert (locally hosted backup)Sustol manufacturer's website
Route: PO, IV, transdermal (Sancuso), SC (Sustol extended release injection)
Extravasation: no information available
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Granisetron (Kytril) patient drug information (UpToDate)Granisetron (Kytril) patient drug information (UpToDate)
==History of changes in FDA indication==
*2001-06-27: Initial FDA approval "for the prevention of: 1) nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. 2) nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation."
*2008-09-12: FDA approved as Sancuso "for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days."
*2016-08-09: FDA approved as Sustol "in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens."
==Also known as==
*Generic names: granisetron extended-release injection for subcutaneous use, granisetron hydrochloride, granisetron hydroxychloride extended release, granisetron transdermal system, granisetronum
*Brand names: Gramatic, Granicip, Graniset, Granisev, Granisol, Granitero, Graniz, Granney, Granny, Granovell, Gratryl, Kytril, Naurif, Sancuso, Sustol
==References==
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Subcutaneous medications
Category:Topical medications
Category:Emesis prevention
Category:Serotonin 5-HT3 antagonists
Category:FDA approved in 1991
Haloperidol (Haldol)

=Mechanism of action=
First-generation typical antipsychotic with antiemetic properties. No known antineoplastic properties.
==Also known as==
*Brand names: Haldol, Heloper, Serenace, Trancodol
Category:Drugs
Category:Intravenous medications
Category:Oral medications
Category:Emesis prevention
Category:Antipsychotic
Category:FDA approved in 1967
Category:WHO Essential Pain and Palliative Care Medicine